EHC Encompass Health Corp

New options for Encompass Health (EHC) with a December 2026 expiration began trading, offering opportunities for sellers of puts or calls to achieve higher premiums due to the extended time value. Stock Options Channel identified a $105.00 strike price put contract and a $115.00 strike price call contract of particular interest, both offering potential YieldBoost returns. These contracts suggest different strategies for investors, leveraging the long expiration period for various risk/reward profiles.

New options contracts for Encompass Health (EHC) with a February 2026 expiration date are now available. BNK Invest's YieldBoost formula highlights a put contract at a $105.00 strike price offering a potential 0.95% return if it expires worthless, and a covered call contract at a $110.00 strike price yielding 4.03% if called away, or a 2.31% boost if it expires worthless. Investors can use these strategies to potentially acquire EHC stock at a discount or generate additional income.

Bellevue Group AG reduced its stake in Encompass Health Corporation (NYSE:EHC) by 23.8% in Q2, selling over 41,000 shares to hold 131,741 shares valued at $16.16 million. Despite this reduction, analysts maintain a "Buy" rating on EHC with an average price target of $142.86, following several upgrades and increased price targets from firms like Bank of America and UBS Group. Encompass Health recently reported quarterly EPS of $0.93 and revenue of $136.3 million, and it announced a quarterly dividend of $0.19 per share.

Bayesian Capital Management LP has initiated a new position in Encompass Health Corporation (NYSE: EHC) during the second quarter, acquiring 20,504 shares valued at approximately $2.51 million. This move is part of broader institutional interest, with other hedge funds also adjusting their stakes in the post-acute healthcare service provider. Encompass Health, with a market capitalization of $10.75 billion, is rated a "Buy" by analysts who have set a consensus price target of $142.86.

Shares of Encompass Health (NYSE:EHC) fell 3.1% due to weak near-term sentiment and concerns about its long-term financial health, including slow sales growth and a dropped free cash flow margin over the last five years. The stock has been underperforming, with a 6.5% loss in the past six months, significantly lagging the S&P 500, despite being up 18% since the beginning of the year. Investors are advised to consider a full analysis report to determine if now is the time to buy.

Marshall Wace LLP has acquired 283,122 shares of Encompass Health Corporation (NYSE:EHC) valued at approximately $34.7 million, representing a 0.28% stake in the company. Encompass Health analysts maintain an average "Buy" rating with a target price of $142.86. The company recently reported Q2 EPS of $0.93 and announced a quarterly dividend of $0.19.